
|Articles|November 6, 2006
Once-daily beta-blocker OK'd for three indications
Advertisement
Carvedilol extended-release capsules (Coreg CR, GlaxoSmithKline), a new once-daily third-generation beta-blocker, has received FDA approval for three indications. The capsule utilizes Flamel Technologies' proprietary Micropump technology, which controls the release of drug from the capsule over 24 hours. Coreg CR can be used to treat hypertension, post-myocardial infarction left ventricular dysfunction, and mild to severe heart failure. According to Glaxo, shipments will begin in the first quarter of 2007.
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
4
What’s Next for Pneumococcal Vaccination? An Expert Weighs In
5






























